NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

Regeneron Pharmaceuticals, Inc. (REGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

REGN

$827.72

−$15.75 (−1.87%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare REGN with… →

REGN Key Statistics

As of Sep 4, 2026
Trading
Open
$840.06
Previous Close
$843.47
Day's Range
825.83–841.54
52-Week Range
541.00–859.34
Volume
561.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.19
Valuation
Market Cap
$85.22B
P/E Ratio
20.49
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.66
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.19
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.49
EPS (ttm)Profit attributable to each share over the last twelve months.
40.40
Financials (FY)
Revenue (FY)
$14.34B+0.99%
Net Income (FY)
$4.50B+2.09%
Profit marginThe share of revenue left as profit after all costs and taxes.
27.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
101.14M
1-Year Return
+46.67%
Dividend and dates
Dividend
$3.76+0.45%
Ex-Dividend Date
August 18, 2026
Earnings Date
October 28, 2026estimated
Avg Volume
851.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

REGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.65%
2025+8.96%
2024−18.90%
2023+21.73%
2022+14.25%
2021+30.72%
2020+28.66%
2019+0.53%
2018−0.65%
2017+2.42%
2016 (partial year)−12.92%

As of September 4, 2026.

REGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.34B$4.50B31.4%
2024$14.20B$4.41B31.1%
2023$13.12B$3.95B30.1%
2022$12.17B$4.34B35.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.34B$12.24B$3.70B$4.50B31.4%
2024$14.20B$12.23B$3.99B$4.41B31.1%
2023$13.12B$11.30B$4.05B$3.95B30.1%
2022$12.17B$10.61B$4.74B$4.34B35.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

REGN Dividend History

$3.52

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$2.823—
2025$3.524—

Most recent payment: $0.94 per share, ex-dividend August 18, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

REGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricREGNBiotechnology medianvs median
P/E20.4912.5763% above
P/S ratio5.4915.2664% below
Profit margin27.87%0.00%27.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Regeneron Pharmaceuticals, Inc. (REGN) is capitalised at $85.22B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 15,410 employees.

The 52-week range on file runs from $541.00 to $859.34. The most recent close on file for REGN is $827.72, dated September 4, 2026. That is −$15.75 (−1.87%) against the previous close. The latest close sits 53% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $14.34B. That is +0.99% against the prior fiscal year, when revenue was $14.20B. The same year closed with net income of $4.50B. That is +2.09% against the prior fiscal year. Profit margin runs at 27.87%. That is 27.9 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 40.4.

Across the 4 fiscal years on file, revenue moves from $12.17B in 2022 to $14.34B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 20.49 times earnings. That is 63.01% above the Biotechnology median of 12.57. On forward earnings the ratio is 13.66. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.19. The price-to-sales ratio is 5.49. On price-to-sales that is 64.06% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +46.67%. Across 10 years the annualized return works out at +7.95%. The reported beta is 0.19. Annualized volatility over the trailing 10 years is 32.18%.

Growth & Income

Shareholders receive a dividend, yielding 0.45% on the latest price. That is 1 percentage points below the Biotechnology median yield of 1.47%. At the indicated rate that is $3.76 a share a year. The ex-dividend date on file is August 18, 2026. Dividends are recorded for 2 calendar years; 2026 shows 3 payments totalling $2.82 a share. The year before, 2025, totalled $3.52 a share.

2026 is still running; the price is +7.65% year to date. The strongest complete calendar year on file is 2021 at +30.72%; the weakest is 2024 at −18.90%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Regeneron Pharmaceuticals, Inc. (REGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
argenx SE ARGX $64.25B 40.1
Moderna, Inc. MRNA $58.11B —

The Biotechnology industry average P/E ratio is 12.6x. Regeneron Pharmaceuticals, Inc. trades at a P/E of 20.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B

 RPRX

Royalty Pharma plc

$36.96B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Visit website →